Biological Intellectual Property Protection Act of 2025
Summary
HR6624 forces a structural onshoring of U.S. synthetic biology IP and manufacturing away from PRC entities. Domestic pure-plays Ginkgo Bioworks ($DNA) and Twist Bioscience ($TWST) are direct beneficiaries, while large biopharma Amgen ($AMGN) and Regeneron ($REGN) face near-term capex pressure but reduced long-term IP risk. The bill advanced out of committee with bipartisan support and has an identical Senate companion bill, increasing passage probability.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6624 forces onshoring of synthetic biology IP and manufacturing away from PRC entities; no direct spending, but massive supply chain restructuring
- 2.Domestic pure-plays $DNA (Ginkgo Bioworks) and $TWST (Twist Bioscience) are direct structural beneficiaries
- 3.Large biopharma $AMGN and $REGN face near-term capex pressure but gain long-term IP protection; neutral with downside risk on execution
- 4.Bipartisan support and a Senate companion bill increase passage probability; floor vote likely within weeks
Market Implications
The bill is a catalyst for the U.S. synthetic biology sector. $DNA at $8.07 with a 30-day gain of 31.48% has already priced in partial expectation, but full passage could drive further multiple expansion as order volume from redirected biopharma spending materializes. $AMGN at $348.89 and $REGN at $706.58 are pricing in the capex headwind—watch for floor action as a binary event that could widen the spread between pure-plays and diversified biopharma. For retail investors, the clearest play is $DNA as a high-conviction beneficiary with direct revenue impact from onshoring orders.
⚡ Government Convergence
Active government convergence in this signal’s sector right now.
Over the last 90 days, 6 separate government actions have converged on Semiconductors / Onshoring. What that means: legislation and executive action are building the policy and funding tailwind behind it, and insiders and private capital are positioning ahead of the spend. When independent channels move together like this — 2 bills, 2 patents, 1 insider buys and 1 congressional trades — it's the clearest early tell that Washington is committing to semiconductors / onshoring, the kind of build-up that reshapes the sector well before it's obvious in the headlines.
Converging government actions
- Insider buyInsider buy: TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD ($301,350) · 2026-07-23
- Congressional tradeCleo Fields bought TSM ($1,001 - $15,000) · 2026-07-31
- PatentPatent: Ciena Corporation — MANAGING SEMICONDUCTOR WAFER AND DIE HANDLING · 2026-07-28
- PatentPatent: Taiwan Semiconductor Manufacturing Co., Ltd. — Wafer Bonding Method and Bonded Device Structure · 2026-07-28
- BillA bill to amend the Arms Export Control Act to address third party transfers of certain defense articles for Ukraine, and for other purposes · 2026-07-30
- BillA bill to amend the Arms Export Control Act to provide for better monitoring and verification of the use of defense articles and defense ser · 2026-07-22
Full Analysis
On April 22, 2026, the House Foreign Affairs Committee ordered HR6624, the Biological Intellectual Property Protection Act of 2025, reported out on a 30-14 vote. The bill, sponsored by Rep. Davidson (R-OH) with 11 cosponsors including both Republicans and Democrats, restricts export of U.S. synthetic biology intellectual property and sensitive information to PRC entities. It now awaits a floor vote in the House. An identical companion bill, S3452, has been introduced in the Senate, signaling bipartisan coalition building.
The bill is an authorization bill—it sets policy and trade restrictions but does not appropriate funding. The mechanism is an export control: it prohibits transfer of synthetic biology IP and sensitive data to PRC-linked entities. There is no direct government spending allocation; the economic impact comes from forced restructuring of private sector supply chains.
Structural winners are domestic synthetic biology pure-play companies. Ginkgo Bioworks ($DNA) at $8.07 has rallied 31.48% in the last 30 days, reflecting market anticipation of this shift. Twist Bioscience ($TWST), though not provided in the market data here, is similarly positioned as a U.S.-based DNA synthesis leader. Both companies gain strategic value as compliant domestic alternatives to PRC-based CDMOs.
Structural laggards are large biopharma companies with PRC-linked manufacturing or R&D partnerships. Amgen ($AMGN) at $348.89 (30-day -0.84%) and Regeneron ($REGN) at $706.58 (30-day -8.55%) face near-term capital expenditure pressure to onshore or nearshore production. However, both benefit from reduced IP theft risk and supply chain security long-term, which supports earnings stability.
Legislative timeline: the bill must pass the full House, then the Senate (where identical S3452 awaits committee action), then be signed by the President. Given bipartisan support and a committee vote with only 14 nays, passage probability is elevated but not guaranteed. Floor action could occur within weeks.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Export restriction on U.S. synthetic biology IP and sensitive information to PRC entities; creates structural barrier to PRC-based CDMO partnerships
Who must act
U.S. biopharma companies and CDMOs currently sourcing synthetic biology services or transferring IP to PRC-linked entities
What happens
U.S. biopharma must onshore or nearshore synthetic biology R&D and production, increasing demand for domestic pure-play platform providers
Stock impact
Ginkgo Bioworks ($DNA) is a U.S.-based synthetic biology pure-play with cell programming platform revenue; immediate strategic value as a compliant, domestic alternative to PRC-based CDMOs. 30-day +31.48% price momentum reflects market pricing in this demand shift.
What the bill does
Export restriction on U.S. synthetic biology IP and sensitive information to PRC entities; restricts DNA synthesis and gene-editing service transfers
Who must act
U.S. biopharma and research institutions using PRC-based gene synthesis or DNA manufacturing services
What happens
Shift of DNA synthesis orders to U.S.-based providers, increasing domestic order volume and pricing power
Stock impact
Twist Bioscience ($TWST) is a U.S. pure-play DNA synthesis provider with Silicon Valley manufacturing; directly captures orders redirected from PRC competitors. Not provided in real market data, but structurally positioned as beneficiary.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
A bill to amend the Arms Export Control Act to provide for better monitoring and verification of the use of defense articles and defense services by countries of concern, and for other purposes.
A bill to amend the Arms Export Control Act to address third party transfers of certain defense articles for Ukraine, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
To Facilitate Positive Adjustment to Competition from Imports of Quartz Surface Products
This proclamation imposes a 4-year tariff-rate quota on imports of quartz surface products (QSP) to protect the domestic industry from serious injury caused by increased imports. It excludes Canada, Mexico, Australia, CAFTA-DR countries, Colombia, Israel, Jordan, Korea, Panama, Peru, Singapore, and CBERA beneficiaries, and provides a developing-country exemption. The action is a safeguard measure under section 202 of the Trade Act of 1974.
Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended, on Recoverable Critical Minerals and Materials
This memorandum invokes the Defense Production Act (DPA) Section 101 to declare that recoverable critical minerals and materials (such as black mass, end-of-life rare-earth magnets, and scrap) are essential to national defense and that the U.S. cannot meet defense needs without disrupting civilian markets. It directs the Secretary of Commerce to issue regulations and take actions—including priority contracts and supply-chain interventions—to rapidly expand domestic recovery and processing of these materials, while explicitly excluding copper scrap already covered by a separate proclamation.
Actions by the United States in the Investigations under Section 301 of the Trade Act of 1974 of the Acts, Policies, and Practices of 60 Economies Related to the Failure of Each Economy to Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced with Forced Labor
This Presidential Memorandum directs the U.S. Trade Representative to impose Section 301 tariffs on imports from 60 economies due to their failure to prohibit or effectively enforce forced labor import bans. Tariffs are set at 10% ad valorem for certain economies with partial enforcement or commitments, and 12.5% for others, with exemptions for raw materials and products causing domestic supply issues, and plans for textile tariff-rate quotas by September 2026. The action aims to eliminate the identified unreasonable trade practices through these tariffs and incentives.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →